raloxifene has been researched along with ethinyl estradiol in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (8.33) | 18.2507 |
2000's | 5 (41.67) | 29.6817 |
2010's | 6 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Adrian, MD; Bryant, HU; Cole, HW; Fuson, TR; Glasebrook, AL; Grese, TA; Magee, DE; Pennington, LD; Phillips, DL; Rowley, ER; Sato, M; Shetler, PK; Short, LL; Sluka, JP; Venugopalan, M; Yang, NN | 1 |
Topliss, JG; Yoshida, F | 1 |
Dansette, PM; Fontana, E; Poli, SM | 1 |
Allan, G; Du, F; Hahn, D; Jain, N; Jian-Zhong, G; Kanojia, RM; Lai, MT; Lundeen, S; Musto, A; Pacia, E; Sui, Z; Xu, J | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Allan, G; Cousineau, M; Du, F; Hahn, D; Jain, N; Jian-Zhong, G; Kanojia, RM; Lai, MT; Li, X; Lundeen, S; Musto, A; Pacia, E; Peng, S; Reuman, M; Ritchie, D; Russell, R; Sui, Z; Xu, J | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Dalvie, D; Hu, Q; Jones, P; Obach, RS; Pryde, DC; Tran, TD | 1 |
Chattopadhyay, N; Gautam, AK; Kureel, J; Maurya, R; Sahai, M; Singh, D; Srivastava, K; Yadav, DK | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Barr, JT; Jones, JP | 1 |
1 review(s) available for raloxifene and ethinyl estradiol
Article | Year |
---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
11 other study(ies) available for raloxifene and ethinyl estradiol
Article | Year |
---|---|
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
Topics: Animals; Bone Density; Cell Division; Cholesterol; Estrogen Antagonists; Female; Gene Expression Regulation; HeLa Cells; Humans; Models, Molecular; Molecular Conformation; Naphthoquinones; Organ Size; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Structure-Activity Relationship; Transforming Growth Factor beta; Tumor Cells, Cultured; Uterus | 1998 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness.
Topics: Animals; Benzopyrans; Body Fluids; Bone Density; Cell Line; Cholesterol; Female; Hot Flashes; Humans; Organ Size; Ovariectomy; Rats; Selective Estrogen Receptor Modulators; Stereoisomerism; Uterus; Vagina; Vaginal Diseases | 2006 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
Topics: Animals; Benzopyrans; Bone Resorption; Cell Line, Tumor; Cholesterol; Drug Evaluation, Preclinical; Drug Stability; Epithelial Cells; Female; Hot Flashes; Humans; Organ Size; Ovariectomy; Postmenopause; Rats; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Substrate Specificity; Uterus; Vagina | 2009 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Aldehyde oxidase: an enzyme of emerging importance in drug discovery.
Topics: Aldehyde Oxidase; Animals; Drug Discovery; Humans; Models, Molecular; Organ Specificity; Oxidation-Reduction; Pharmaceutical Preparations; Pharmacokinetics; Species Specificity; Substrate Specificity | 2010 |
Synthetic analogs of daidzein, having more potent osteoblast stimulating effect.
Topics: Animals; Bone Marrow Cells; Bone Morphogenetic Protein 2; Calcification, Physiologic; Cell Differentiation; Cells, Cultured; Gene Expression Regulation; Isoflavones; Osteoblasts; Osteocalcin; Phytoestrogens; Rats; RNA, Messenger; Skull | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.
Topics: Aldehyde Oxidase; Aminoacridines; Chromatography, Liquid; Enzyme Inhibitors; Humans; Liver; Magnetic Resonance Spectroscopy; Mass Spectrometry; Oxidation-Reduction | 2013 |